Glenmark Pharmaceuticals receives ANDA approval for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceuticals company has received final approval by the United States Food & Drug Administration (U.S. FDA) for Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine® Tablets, 5 mg and 10 mg, of GlaxoSmithKline. Glenmark's Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.

According to IQVIA™ sales data for the 12-month period ending January 2023, the Compazine® Tablets, 5 mg and 10 mg market achieved annual sales of approximately $26.9 million*.

Glenmark's current portfolio consists of 182 products authorized for distribution in the U.S. marketplace and 46 ANDA's pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 440.75 as compared to the previous close of Rs. 432.60. The total number of shares traded during the day was 56554 in over 2345 trades.

The stock hit an intraday high of Rs. 441.60 and intraday low of 433.15. The net turnover during the day was Rs. 24789696.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 USFDA FinalApproval ProchlorperazineMaleateTablets